05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of cardiovascular, cardiopulmonary, pulmonary, and vascular diseases; Pharmaceutical preparations for the treatment of pulmonary hypertension
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of cardiovascular, cardiopulmonary, pulmonary, and vascular diseases; Pharmaceutical preparations for the treatment of pulmonary hypertension
3.
TREPROSTINIL DERIVATIVES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS
Provided are treprostinil derivatives with a reduced ability to form undesired impurities in a pharmaceutical formulation, such as a dry powder formulation, further containing a carboxyl group containing inactive ingredient, such as fumaryl dikctopiperazinc.
12 - Véhicules; appareils de locomotion par terre, par air ou par eau; parties de véhicules
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
(1) Aircraft; Electrically powered aircraft; Vertical take-off and landing (VTOL) aircraft (1) Research and development in the field of electrically powered aircraft
12 - Véhicules; appareils de locomotion par terre, par air ou par eau; parties de véhicules
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
(1) Aircraft; Electrically powered aircraft; Vertical take-off and landing (VTOL) aircraft (1) Research and development in the field of electrically powered aircraft
12 - Véhicules; appareils de locomotion par terre, par air ou par eau; parties de véhicules
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
(1) Aircraft; Electrically powered aircraft; Vertical take-off and landing (VTOL) aircraft (1) Research and development in the field of electrically powered aircraft
Methods of treating of interstitial lung disease, reducing pulmonary function decline in a subject with interstitial lung disease (ILD), and increasing forced vital capacity (FVC) in a subject suffering from ILD are provided, wherein the methods include administration of treprostinil.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A method of producing an oral osmotic pharmaceutical delivery system by using a statistical modeling. The method includes determining a desired average dissolution profile for the active pharmaceutical ingredient; and controlling tablet strength, acetyl content of the cellulose acetate and weight gain of the semi-permeable membrane of the tablet to produce a pharmaceutical batch of tablets having the desired dissolution profile.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/28 - DragéesPilules ou comprimés avec revêtements
12 - Véhicules; appareils de locomotion par terre, par air ou par eau; parties de véhicules
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Aircraft; Electrically powered aircraft; Vertical take-off and landing (VTOL) aircraft Research and development in the field of electrically powered aircraft
12 - Véhicules; appareils de locomotion par terre, par air ou par eau; parties de véhicules
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Aircraft; Electrically powered aircraft; Vertical take-off and landing (VTOL) aircraft Research and development of technology in the field of electrically powered aircraft
11.
A METHOD OF PRODUCING AN ORAL OSMOTIC PHARMACEUTICAL DELIVERY SYSTEM AND A PHARMACEUTICAL BATCH PRODUCED USING THE SAME
A method of producing an oral osmotic pharmaceutical delivery system by using a statistical modeling. The method includes determining a desired average dissolution profile for the active pharmaceutical ingredient; and controlling tablet strength, acetyl content of the cellulose acetate and weight gain of the semi-permeable membrane of the tablet to produce a pharmaceutical batch of tablets having the desired dissolution profile.
A61K 9/28 - DragéesPilules ou comprimés avec revêtements
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
12.
CRYSTALLINE PROSTACYCLIN (IP) RECEPTOR AGONIST AND USES THEREOF
Described herein are crystalline forms of a prostacyclin (IP) receptor agonist compound, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist compound.
C07C 271/28 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec l'atome d'azote d'au moins un des groupes carbamate lié à un atome de carbone d'un cycle aromatique à six chaînons à un atome de carbone d'un cycle aromatique à six chaînons non condensé
13.
A HIGH RESOLUTION PRINTING SYSTEM AND A METHOD OF ALIGNING PIXELATED TILES
A three-dimensional printing apparatus is configured to manufacture a 3D article in a layer-layer manner. The 3D printing apparatus includes a projector configured to selectively irradiate a photosensitive apparatus along a horizontal build plane defined along X and Y axes. The projector is coupled to a lateral movement mechanism configured to laterally scan the projector along X' and Y' axial movement coordinates. The X' and Y' axial movement coordinates are not exactly aligned with the X and Y axes respectively. For individual layers of the 3D article, the projector is configured to irradiate a sequence of adjacent pixelated tiles within the build plane. Before irradiating the sequence of tiles, the projector is configured to operate a camera and to align leading (46, 46-1) and trailing edges (48, 48-2) of the tiles along each of X' and Y'.
B29C 64/135 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant des couches de liquide à solidification sélective caractérisés par la source d'énergie à cet effet, p. ex. par irradiation globale combinée avec un masque la source d’énergie étant concentrée, p. ex. lasers à balayage ou sources lumineuses focalisées
B29C 64/236 - Moyens d’entraînement pour un mouvement dans une direction dans le plan d’une couche
A three-dimensional (3D) printing apparatus is configured to manufacture a 3D article in a layer-layer manner. The 3D printing apparatus includes a projector configured to selectively irradiate a photosensitive apparatus along a horizontal build plane defined along X and Y axes. The projector is coupled to a lateral movement mechanism configured to laterally scan the projector along X′ and Y′ axial movement coordinates. The X′ and Y′ axial movement coordinates are not exactly aligned with the X and Y axes respectively. For individual layers of the 3D article, the projector is configured to irradiate a sequence of adjacent pixelated tiles within the build plane. Before irradiating the sequence of tiles, the projector is configured to operate a camera and to align leading and trailing edges of the tiles along each of X′ and Y′.
B29C 64/393 - Acquisition ou traitement de données pour la fabrication additive pour la commande ou la régulation de procédés de fabrication additive
B29C 64/129 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant des couches de liquide à solidification sélective caractérisés par la source d'énergie à cet effet, p. ex. par irradiation globale combinée avec un masque
B29C 64/232 - Moyens d’entraînement pour un mouvement le long de l'axe orthogonal au plan d’une couche
B29C 64/255 - Enceintes pour le matériau de construction, p. ex. récipients pour poudre
C07C 51/41 - Préparation de sels d'acides carboxyliques par conversion de ces acides ou de leurs sels en sels ayant la même partie acide carboxylique
C07C 59/72 - Composés non saturés contenant des groupes éther, des groupes , des groupes ou des groupes contenant des cycles aromatiques à six chaînons et d'autres cycles
16.
MEDIA COMPOSITION FOR INDUCED PLURIPOTENT STEM CELL DERIVED ENDOTHELIAL CELL GROWTH, MONOLAYER FORMATION, AND CELL-CELL CONTACT FORMATION
e.ge.g., culture media) for culturing iPS cells, such as iPS-endothelial cells (iPS-ECs). The present disclosure also provides iPS-EC cultures comprising iPS-ECs and a culture medium.
The present disclosure relates generally to, among other things, methods and compositions (e.g., culture media) for culturing iPS cells, such as iPS-endothelial cells (IPS-ECs). The present disclosure also provides iPS-EC cultures comprising iPS-ECs and a culture medium.
The present disclosure relates to CCL20 promoters derived from the regulatory region of the CCL20 gene that stimulate gene expression in response to inflammation. These CCL20 promoters, which can be stimulated by an endogenous or exogenous cytokine, can be used to control the timing of the expression of a heterologous gene. The present disclosure also relates to expression cassettes or vectors comprising the CCL20 promoters of the present disclosure operably linked to a nucleic acid sequence encoding, e.g., a polypeptide of interest, as well as delivery systems (e.g., viral particles, lipid vesicles, or nanoparticles) or cells comprising such expression cassettes or vectors. The present disclosure also relates to the use of the promoters, expression cassettes, vectors, delivery systems, or cells in the treatment of diseases related to inflammation, or for recombinant gene expression.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 38/00 - Préparations médicinales contenant des peptides
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
19.
METHODS FOR CREATING REGULATORY T CELLS (TREGS) USING GENOME ENGINEERING
Provided are methods, polynucleotides and compositions for the generation of engineered Treg cells. The methods, polynucleotides and compositions enable the reprogramming of hematopoietic cells into Treg cells by constitutive or regulated expression of FOXP3 in engineered cells such that the engineered Treg cells can suppress the activation and proliferation of responder T cells.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
The present disclosure provides novel serology methods for detecting viremic or latent zoonotic viral infections, such as porcine cytomegalovirus (PCMV) or Porcine lymphotropic herpesvirus (PLHV) infections, in a subject at any stage of development. More specifically, the present disclosure provides an automated multiplexed immunoassay for the rapid and simultaneous detection of one or more anti-PCMV antibodies or anti-PLHV antibodies in biological fluids of a subject suspected of being infected with PCMV or PLHV.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
Modular synthetic receptors are provided. The synthetic receptors may include an extracellular domain capable of binding to one or more ligand molecules and may be released from the synthetic receptor after binding, a transmembrane domain derived from the Notch receptor, and an intracellular domain which may have one or more functional activities when released from the synthetic receptor. A method of use for the synthetic receptors is also provided, wherein upon binding of the extracellular domain to a specific ligand, the synthetic receptor undergoes proteolytic cleavage to release either or both the extracellular and intracellular domains. The extracellular binding domain, if released, may continue to bind to its cognate ligand and may carry one or more additional functional activities and the intracellular domain, if released, may stimulate or inhibit one or more intracellular activities.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
22.
SEROLOGY ASSAY FOR THE DETECTION OF PORCINE VIRUSES
The present disclosure provides novel serology methods for detecting viremic or latent zoonotic viral infections, such as porcine cytomegalovirus (PCMV) or Porcine lymphotropic herpesvirus (PLHV) infections, in a subject at any stage of development. More specifically, the present disclosure provides an automated multiplexed immunoassay for the rapid and simultaneous detection of one or more anti-PCMV antibodies or anti-PLHV antibodies in biological fluids of a subject suspected of being infected with PCMV or PLHV.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
Disclosed herein are drug release polymer compounds and compositions comprising prostacyclin compounds of Formula (I), and methods of preparing the same. A preferred polymer has a repeating unit of the following structure:
Disclosed herein are drug release polymer compounds and compositions comprising prostacyclin compounds of Formula (I), and methods of preparing the same. A preferred polymer has a repeating unit of the following structure:
A61K 31/5575 - Eicosanoïdes, p. ex. leucotriènes ayant un cycle cyclopentane, p. ex. prostaglandine E2, prostaglandine F2-alpha
A61K 31/558 - Eicosanoïdes, p. ex. leucotriènes ayant des hétérocycles contenant l'oxygène comme seul hétéro-atome du cycle, p. ex. thromboxanes
C07C 67/08 - Préparation d'esters d'acides carboxyliques par réaction d'acides carboxyliques ou d'anhydrides symétriques avec le groupe hydroxyle ou O-métal de composés organiques
24.
BICISTRONIC CONSTRUCTS FOR ALLOGENEIC GENE THERAPY
The present disclosure relates to bicistronic polypeptide constructs for use in allogeneic gene therapy, for example, CAR-T cell therapy. The bicistronic constructs comprise first polynucleotide encoding a therapeutic molecule (e.g., a CAR-T or an antibody) and a second polynucleotide encoding an Immune Surveillance Masking Molecule (ISMM). The ISMM comprises a human leukocyte antigen-E genetically fused to a non-functional version, e.g., a fragment, of the protein knock-out by the insertion of the bicistronic construct, e.g., beta-2 microglobulin or B2M. Also provided are vectors comprising the bicistronic constructs, cells (e.g., CAR-T cells), and methods of use. Also provided are kits and articles of manufacture. The present disclosure also provides four novel insertion sites that can be used to insert an expression construct in the B2M gene.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
Provided are methods, polynucleotides and compositions for the generation of engineered Treg cells. The methods, polynucleotides and compositions enable the reprogramming of hematopoietic cells into Treg cells by constitutive or regulated expression of FOXP3 in engineered cells such that the engineered Treg cells can suppress the activation and proliferation of responder T cells.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A method of modifying a surface of a three-dimensional (3D) article includes immersing at least one part of the 3D article in a buffered solution of functionalized peptides, allowing reaction between the functionalized peptides and reactive groups on the surface of the 3D article; and washing the at least one part of the 3D article to remove unreacted functionalized peptides. The surface-modified 3D article includes a plurality of peptides covalently bonded to the surface of the 3D article via a cysteine bridge. The surface- modified 3D article can be used as a scaffold for the formation of biological tissue or bodily implants.
An automated bioreactor system for decellularizing an organ includes a main chamber for containing the organ. The system further includes a reagent chamber containing a liquid phase reagent. A reagent conduit delivers the liquid phase reagent to the main chamber, and a perfusion conduit delivers the reagent from the reagent outlet in the main chamber into the organ. A perfusion pump drives the flow of the reagent. A perfusion pressure sensor detects a pressure of the flowing reagent. A control system controls the perfusion pump to drive the flow of the reagent based on a received input representative of a desired pressure and a received input of the detected pressure. The control system may automatically perform all of the steps of a decellularization protocol based on sensor input. An automated waste decontamination system may also be provided.
A61L 2/00 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
G01G 19/00 - Appareils ou méthodes de pesée adaptés à des fins particulières non prévues dans les groupes
G01K 13/02 - Thermomètres spécialement adaptés à des fins spécifiques pour mesurer la température de fluides en mouvement ou de matériaux granulaires capables de s'écouler
G01L 7/00 - Mesure de la pression permanente ou quasi permanente d’un fluide ou d’un matériau solide fluent par des éléments mécaniques ou hydrauliques sensibles à la pression
A method of modifying a surface of a three-dimensional (3D) article includes immersing at least one part of the 3D article in a buffered solution of functionalized peptides, allowing reaction between the functionalized peptides and reactive groups on the surface of the 3D article; and washing the at least one part of the 3D article to remove unreacted functionalized peptides. The surface-modified 3D article includes a plurality of peptides covalently bonded to the surface of the 3D article via a cysteine bridge. The surface-modified 3D article can be used as a scaffold for the formation of biological tissue or bodily implants.
The present disclosure relates to CCL20 promoters derived from the regulatory region of the CCL20 gene that stimulate gene expression in response to inflammation. These CCL20 promoters, which can be stimulated by an endogenous or exogenous cytokine, can be used to control the timing of the expression of a heterologous gene. The present disclosure also relates to expression cassettes or vectors comprising the CCL20 promoters of the present disclosure operably linked to a nucleic acid sequence encoding, e.g., a polypeptide of interest, as well as delivery systems (e.g., viral particles, lipid vesicles, or nanoparticles) or cells comprising such expression cassettes or vectors. The present disclosure also relates to the use of the promoters, expression cassettes, vectors, delivery systems, or cells in the treatment of diseases related to inflammation, or for recombinant gene expression.
The present disclosure relates to bicistronic polypeptide constructs for use in allogeneic gene therapy, for example, CAR-T cell therapy. The bicistronic constructs comprise first polynucleotide encoding a therapeutic molecule (e.g., a CAR-T or an antibody) and a second polynucleotide encoding an Immune Surveillance Masking Molecule (ISMM). The ISMM comprises a human leukocyte antigen-E genetically fused to a non-functional version, e.g., a fragment, of the protein knock-out by the insertion of the bicistronic construct, e.g., beta-2 microglobulin or B2M. Also provided are vectors comprising the bicistronic constructs, cells (e.g., CAR-T cells), and methods of use. Also provided are kits and articles of manufacture. The present disclosure also provides four novel insertion sites that can be used to insert an expression construct in the B2M gene.
Provided are novel treprostinil derivatives, including treprostinil prodrugs and treprostinil analogs, as well as methods of making and using these compounds.
A61K 31/222 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine avec des composés ayant des groupes aromatiques, p. ex. dipivéfrine, ibopamine
A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p. ex. fosfosal, dichlorvos, malathion
C07C 69/712 - Éthers le groupe hydroxyle de l'ester étant éthérifié par un composé hydroxylé dont le groupe hydroxyle est lié à un atome de carbone d'un cycle aromatique à six chaînons
Provided herein are methods which alter the mechanical and biological properties of polymeric materials. Also provided are compositions comprising the polymeric materials having said properties.
B29C 64/188 - Procédés de fabrication additive impliquant des opérations supplémentaires effectuées sur les couches ajoutées, p. ex. lissage, meulage ou contrôle d’épaisseur
C07C 51/41 - Préparation de sels d'acides carboxyliques par conversion de ces acides ou de leurs sels en sels ayant la même partie acide carboxylique
C07C 59/72 - Composés non saturés contenant des groupes éther, des groupes , des groupes ou des groupes contenant des cycles aromatiques à six chaînons et d'autres cycles
36 - Services financiers, assurances et affaires immobilières
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
Patient support services on behalf of pharmaceutical manufacturers for the benefit of patients of pharmaceutical manufacturers including enrolling patients of pharmaceutical manufacturers in support programs that enables the patients to view, track and manage the support program wherein the patient support program provides pharmaceutical product and medication education, medication adherence support, visibility into medication delivery and case status, clinical support services, access to financial assistance programs, payer coverage status updates, patient engagement services and reminders and notifications Providing information to patients and caregivers on available financial support for pharmaceutical treatments Educational services, namely, online and telephone coaching for patients and caregivers about disease management and treatment information to improve understanding by patients and caregivers about pharmaceutical treatments and administration
Provided are novel methods of treating pulmonary hypertension comprising monitoring mean pulmonary arterial pressure in a subject, administering a first therapeutically effective amount of a pulmonary vasodilator when mean pulmonary pressure exceeds a threshold value in the subject, and administering an increasing dose of the pulmonary vasodilator until mean pulmonary arterial pressure is reduced.
A61K 31/5575 - Eicosanoïdes, p. ex. leucotriènes ayant un cycle cyclopentane, p. ex. prostaglandine E2, prostaglandine F2-alpha
A61K 31/5585 - Eicosanoïdes, p. ex. leucotriènes ayant des hétérocycles contenant l'oxygène comme seul hétéro-atome du cycle, p. ex. thromboxanes ayant des cycles à cinq chaînons contenant l'oxygène comme seul hétéro-atome du cycle, p. ex. prostacycline
Provided are novel treprostinil derivatives, including treprostinil prodrugs and treprostinil analogs, as well as methods of making and using these compounds.
C07C 69/63 - Esters contenant des atomes d'halogène d'acides saturés
C07C 69/675 - Esters d'acides carboxyliques dont le groupe carboxyle estérifié est lié à un atome de carbone acyclique et dont l'un des groupes OH, O-métal, —CHO, céto, éther, acyloxy, des groupes , des groupes ou des groupes se trouve dans la partie acide d'acides saturés d'acides hydroxycarboxyliques saturés
Provided are novel methods of treating pulmonary hypertension comprising monitoring mean pulmonary arterial pressure in a subject, administering a first therapeutically effective amount of a pulmonary vasodilator when mean pulmonary pressure exceeds a threshold value in the subject, and administering an increasing dose of the pulmonary vasodilator until mean pulmonary arterial pressure is reduced.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
The present disclosure relates to methods of differentiating pluripotent stem cells into endothelial cells. The present disclosure also relates to endothelial cells made by such methods, organoids containing such endothelial cells, and methods of use thereof. The present disclosure also relates to differentiation media for use in the same.
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
40.
REMUNITYPRO FOR REMODULIN (TREPROSTINIL) INJECTION
A method of manufacturing a three-dimensional (3D) article includes operating a print engine to fabricate a composite structure including the 3D article coupled to a support structure, removing the composite structure from the fluid tank, and peeling the inside surface of the sheath away from the outer surface of the article, peeling progressively breaks the plurality of strands. The support structure includes a conformal sheath having an inside surface that follows the outer surface of the 3D article with a gap between the inside surface of the sheath and the outer surface of the article, and a plurality of strands that span the gap and individually have opposed ends that are coupled to the inside surface of the sheath and the outer surface of the article to maintain the gap, the gap filled with the photocurable liquid ink.
B29C 64/124 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant des couches de liquide à solidification sélective
B29C 64/40 - Structures de support des objets en 3D pendant la fabrication, lesdites structures devant être sacrifiées après réalisation de la fabrication
The present disclosure provides for treating pulmonary hypertension by administering to a subject suffering from pulmonary hypertension a therapeutically effective amount of a non-oral therapeutic agent for treating pulmonary hypertension followed by an orally administered form of a therapeutic agent for treating pulmonary hypertension, wherein the amount of non-oral therapeutic agent is sufficient to allow for an increased amount of the orally administered therapeutic agent to thereafter be administered compared to a subject who is not previously treated with the non-oral therapeutic agent.
An advanced manufactured interpenetrating polymer network (AM-IPN) comprising: a primary polymer network; a secondary polymer network, wherein the secondary polymer network is bonded to the primary polymer network via one or more crosslinks, wherein one or more of the primary polymer network, the secondary polymer network and the one or more crosslinks are printed using a synthetic bioink is disclosed. Methods of making and using are also disclosed.
C09D 4/06 - Compositions de revêtement, p. ex. peintures, vernis ou vernis-laques, à base de composés non macromoléculaires organiques ayant au moins une liaison non saturée carbone-carbone polymérisable en combinaison avec un composé macromoléculaire autre qu'un polymère non saturé des groupes
B33Y 70/00 - Matériaux spécialement adaptés à la fabrication additive
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
A method of manufacturing a three-dimensional (3D) article includes operating a print engine to fabricate a composite structure including the 3D article coupled to a support structure, removing the composite structure from the fluid tank, and peeling the inside surface of the sheath away from the outer surface of the article, peeling progressively breaks the plurality of strands. The support structure includes a conformal sheath having an inside surface that follows the outer surface of the 3D article with a gap between the inside surface of the sheath and the outer surface of the article, and a plurality of strands that span the gap and individually have opposed ends that are coupled to the inside surface of the sheath and the outer surface of the article to maintain the gap, the gap filled with the photocurable liquid ink.
B29C 64/40 - Structures de support des objets en 3D pendant la fabrication, lesdites structures devant être sacrifiées après réalisation de la fabrication
B29C 64/124 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant des couches de liquide à solidification sélective
The present disclosure provides for treating pulmonary hypertension by administering to a subject suffering from pulmonary hypertension a therapeutically effective amount of a non-oral therapeutic agent for treating pulmonary hypertension followed by an orally administered form of a therapeutic agent for treating pulmonary hypertension, wherein the amount of non-oral therapeutic agent is sufficient to allow for an increased amount of the orally administered therapeutic agent to thereafter be administered compared to a subject who is not previously treated with the non-oral therapeutic agent.
A61K 31/5585 - Eicosanoïdes, p. ex. leucotriènes ayant des hétérocycles contenant l'oxygène comme seul hétéro-atome du cycle, p. ex. thromboxanes ayant des cycles à cinq chaînons contenant l'oxygène comme seul hétéro-atome du cycle, p. ex. prostacycline
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/222 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine avec des composés ayant des groupes aromatiques, p. ex. dipivéfrine, ibopamine
A61K 31/6615 - Composés ayant plusieurs groupes d'acide du phosphore estérifiés, p. ex. triphosphate d'inositol, acide phytique
48.
TREATMENT OF PULMONARY ARTERIAL HYPERTENSION WITH PROSTACYCLIN-TREATED ENDOTHELIAL PROGENITOR CELLS
The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.
A61K 31/5585 - Eicosanoïdes, p. ex. leucotriènes ayant des hétérocycles contenant l'oxygène comme seul hétéro-atome du cycle, p. ex. thromboxanes ayant des cycles à cinq chaînons contenant l'oxygène comme seul hétéro-atome du cycle, p. ex. prostacycline
A61K 35/02 - Préparations médicinales contenant des substances ou leurs produits de réaction de constitution non déterminée à partir de substances inanimées
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Human organs, organ tissue, and organ parts for transplantation; medical implant devices, namely, implants consisting primarily of biological materials, and implants consisting of a combination of biological and artificial materials, all of which are derived, at least in part, from human organ tissue for use in transplantation Medical and scientific research in the field of preservation, modification, and engineering of human organs Specialized medical services, namely, rehabilitation of human organs, organ tissue, and organ parts for transplantation; health care services, namely, services to perfuse human organs, organ tissue, and organ parts after recovery from an organ donor and before transplantation into a recipient
50.
TREATMENT OF VASCULOPATHY WITH PROSTACYCLIN AND MESENCHYMAL STEM CELLS
Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
C07C 59/72 - Composés non saturés contenant des groupes éther, des groupes , des groupes ou des groupes contenant des cycles aromatiques à six chaînons et d'autres cycles
C07D 207/16 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
C07D 211/60 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
C07D 265/30 - Oxazines-1, 4Oxazines-1, 4 hydrogénées non condensées avec d'autres cycles
C07D 317/40 - Carbonate de vinylèneCarbonates de vinylène substitués
The present disclosure relates to methods of differentiating pluripotent stem cells into stromal cells or pericytes. The present disclosure also relates to stromal cells or pericytes made by such methods, organoids containing such stromal cells or pericytes, and methods of using the same. The present disclosure also relates to differentiation media for use in the same.
C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
54.
Methods for Differentiating Epithelial or Basal Cells
The present disclosure relates to methods of differentiating pluripotent stem cells or lung progenitor cells into epithelial or basal cells. The present disclosure also relates to epithelial or basal cells made by such methods, organoids containing such epithelial or basal cells, and methods of using the same. The present disclosure also relates to differentiation media for use in the same.
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
The present disclosure relates to methods of differentiating pluripotent stem cells or lung progenitor cells into alveolar type 2 (AT2) cells. The present disclosure also relates to AT2 cells made by such methods, organoids containing such AT2 cells and methods of using the same. The present disclosure also relates to differentiation media for use in the same.
An advanced manufactured interpenetrating polymer network (AM-IPN) comprising: a primary polymer network; a secondary polymer network, wherein the secondary polymer network is bonded to the primary polymer network via one or more crosslinks, wherein one or more of the primary polymer network, the secondary polymer network and the one or more crosslinks are printed using a synthetic bioink is disclosed. Methods of making and using are also disclosed.
An advanced manufactured transwell (AM-transwell), the AM-transwell comprises: a lower chamber; an upper chamber; a membrane disposed between the lower chamber and the upper chamber; and one or more legs. The one or more legs form at least a portion of the lower chamber. One or more of the lower chambers, the upper chamber, the membrane and the one or more legs is printed using a synthetic bioink. Methods for making and using the AM-transwell are also disclosed.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
B33Y 80/00 - Produits obtenus par fabrication additive
58.
TRANSWELL FOR CELL CULTURE, METHOD OF MANUFACTURING WITH SYNTHETIC BIOINK AND IN VITRO TISSUE MODELS
An advanced manufactured transwell (AM-transwell), the AM-transwell comprises: a lower chamber; an upper chamber; a membrane disposed between the lower chamber and the upper chamber; and one or more legs. The one or more legs form at least a portion of the lower chamber. One or more of the lower chambers, the upper chamber, the membrane and the one or more legs is printed using a synthetic bioink. Methods for making and using the AM-transwell are also disclosed.
The present disclosure relates to methods of differentiating pluripotent stem cells into endothelial cells. The present disclosure also relates to endothelial cells made by such methods, organoids containing such endothelial cells, and methods of use thereof. The present disclosure also relates to differentiation media for use in the same.
The present disclosure relates to methods of differentiating pluripotent stem cells or lung progenitor cells into epithelial or basal cells. The present disclosure also relates to epithelial or basal cells made by such methods, organoids containing such epithelial or basal cells, and methods of using the same. The present disclosure also relates to differentiation media for use in the same.
The present disclosure relates to methods of differentiating pluripotent stem cells or lung progenitor cells into alveolar type 2 (AT2) cells. The present disclosure also relates to AT2 cells made by such methods, organoids containing such AT2 cells and methods of using the same. The present disclosure also relates to differentiation media for use in the same.
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
62.
METHODS FOR DIFFERENTIATING STROMAL CELLS OR PERICYTES
The present disclosure relates to methods of differentiating pluripotent stem cells into stromal cells or pericytes. The present disclosure also relates to stromal cells or pericytes made by such methods, organoids containing such stromal cells or pericytes, and methods of using the same. The present disclosure also relates to differentiation media for use in the same.
Described herein are ralinepag prodrugs, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist compound, such as but not limited to pulmonary hypertension (PH) diseases.
C07C 271/28 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec l'atome d'azote d'au moins un des groupes carbamate lié à un atome de carbone d'un cycle aromatique à six chaînons à un atome de carbone d'un cycle aromatique à six chaînons non condensé
C07D 317/40 - Carbonate de vinylèneCarbonates de vinylène substitués
C07C 311/51 - Y étant un atome d'hydrogène ou de carbone
C07D 211/32 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés, substitués par des atomes d'oxygène ou de soufre liés par des liaisons doubles ou par deux atomes d'oxygène ou de soufre, liés au même atome de carbone par des liaisons simples par des atomes d'oxygène
Described herein are crystalline forms of a prostacyclin (IP) receptor agonist compound, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist compound.
C07C 271/28 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec l'atome d'azote d'au moins un des groupes carbamate lié à un atome de carbone d'un cycle aromatique à six chaînons à un atome de carbone d'un cycle aromatique à six chaînons non condensé
Nebulizers and inhalers for administering medication in the form of a mist inhaled into the lungs, for treatment of pulmonary hypertension and heart and lung diseases
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Software as a Service (SAAS) services featuring software for monitoring the delivery of and implant procedure for organ transplants, for monitoring and reporting statistics on the health of the organ, its viability for transport and transplant, its current location and times for various events involved in the organ delivery and transplant process, and enabling instant user access for, and communication among, all parties involved in the organ delivery and transplant process, including doctors, hospital and transport staff, and medical and medical research personnel
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Human organs, organ tissue, and organ parts for transplantation; medical implant devices, namely, implants consisting primarily of biological materials, and implants consisting of a combination of biological and artificial materials, all of which are derived, at least in part, from human organ tissue for use in transplantation Medical and scientific research in the field of preservation, modification, and engineering of human organs Specialized medical services, namely, rehabilitation of human organs, organ tissue, and organ parts for transplantation; health care services, namely, services to perfuse human organs, organ tissue, and organ parts after recovery from an organ donor and before transplantation into a recipient
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Human organs, organ tissue, and organ parts for transplantation; medical implant devices, namely, implants consisting primarily of biological materials, and implants consisting of a combination of biological and artificial materials, all of which are derived, at least in part, from human organ tissue for use in transplantation Medical and scientific research in the field of preservation, modification, and engineering of human organs Specialized medical services, namely, rehabilitation of human organs, organ tissue, and organ parts for transplantation; health care services, namely, services to perfuse human organs, organ tissue, and organ parts after recovery from an organ donor and before transplantation into a recipient
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Human organs, organ tissue, and organ parts for transplantation; medical implant devices, namely, implants consisting primarily of biological materials, and implants consisting of a combination of biological and artificial materials, all of which are derived, at least in part, from human organ tissue for use in transplantation Medical and scientific research in the field of preservation, modification, and engineering of human organs Specialized medical services, namely, rehabilitation of human organs, organ tissue, and organ parts for transplantation; health care services, namely, services to perfuse human organs, organ tissue, and organ parts after recovery from an organ donor and before transplantation into a recipient
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Human organs, organ tissue, and organ parts for transplantation; medical implant devices, namely, implants consisting primarily of biological materials, and implants consisting of a combination of biological and artificial materials, all of which are derived, at least in part, from human organ tissue for use in transplantation Medical and scientific research in the field of preservation, modification, and engineering of human organs Specialized medical services, namely, rehabilitation of human organs, organ tissue, and organ parts for transplantation; health care services, namely, services to perfuse human organs, organ tissue, and organ parts after recovery from an organ donor and before transplantation into a recipient
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Human organs, organ tissue, and organ parts for transplantation; medical implant devices, namely, implants consisting primarily of biological materials, and implants consisting of a combination of biological and artificial materials, all of which are derived, at least in part, from human organ tissue for use in transplantation Medical and scientific research in the field of preservation, modification, and engineering of human organs Specialized medical services, namely, rehabilitation of human organs, organ tissue, and organ parts for transplantation; health care services, namely, services to perfuse human organs, organ tissue, and organ parts after recovery from an organ donor and before transplantation into a recipient
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Human organs, organ tissue, and organ parts for transplantation; medical implant devices, namely, implants consisting primarily of biological materials, and implants consisting of a combination of biological and artificial materials, all of which are derived, at least in part, from human organ tissue for use in transplantation Medical and scientific research in the field of preservation, modification, and engineering of human organs Specialized medical services, namely, rehabilitation of human organs, organ tissue, and organ parts for transplantation; health care services, namely, services to perfuse human organs, organ tissue, and organ parts after recovery from an organ donor and before transplantation into a recipient
73.
PROCESS TO PREPARE TREPROSTINIL, THE ACTIVE INGREDIENT IN REMODULIN®
This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
C07C 51/08 - Préparation d'acides carboxyliques, de leurs sels, halogénures ou anhydrides à partir de nitriles
C07C 51/41 - Préparation de sels d'acides carboxyliques par conversion de ces acides ou de leurs sels en sels ayant la même partie acide carboxylique
C07C 213/08 - Préparation de composés contenant des groupes amino et hydroxy, amino et hydroxy éthérifiés ou amino et hydroxy estérifiés liés au même squelette carboné par des réactions n'impliquant pas la formation de groupes amino, de groupes hydroxy ou de groupes hydroxy éthérifiés ou estérifiés
C07C 59/72 - Composés non saturés contenant des groupes éther, des groupes , des groupes ou des groupes contenant des cycles aromatiques à six chaînons et d'autres cycles
C07C 405/00 - Composés contenant un cycle à cinq chaînons comportant deux chaînes latérales en position ortho l'une par rapport à l'autre et comportant des atomes d'oxygène directement attachés au cycle en position ortho par rapport à l'une des chaînes latérales, une des chaînes latérales contenant, non directement attaché au cycle, un atome de carbone ayant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, et l'autre chaîne latérale comportant des atomes d'oxygène attachés en position gamma du cycle, p. ex. prostaglandines
C07C 253/00 - Préparation de nitriles d'acides carboxyliques
refrigerated transport containers for use in the cold storage of organs for transplant nonmetal and non-paper containers for storage and transport of organs for transplant
Described herein are ralinepag prodrugs, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist compound, such as but not limited to pulmonary hypertension (PH) diseases.
A61K 31/325 - Acides carbamiquesAcides thiocarbamiquesLeurs anhydrides ou sels
A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p. ex. éthers en couronne, guanadrel
A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
C07C 271/28 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec l'atome d'azote d'au moins un des groupes carbamate lié à un atome de carbone d'un cycle aromatique à six chaînons à un atome de carbone d'un cycle aromatique à six chaînons non condensé
C07C 311/51 - Y étant un atome d'hydrogène ou de carbone
Described herein are ralinepag prodrugs, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist compound, such as but not limited to pulmonary hypertension (PH) diseases.
C07C 271/28 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec l'atome d'azote d'au moins un des groupes carbamate lié à un atome de carbone d'un cycle aromatique à six chaînons à un atome de carbone d'un cycle aromatique à six chaînons non condensé
A61K 31/325 - Acides carbamiquesAcides thiocarbamiquesLeurs anhydrides ou sels
A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p. ex. éthers en couronne, guanadrel
A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
Described herein are crystalline forms of a prostacyclin (IP) receptor agonist compound, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist compound.
A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
C07C 271/28 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec l'atome d'azote d'au moins un des groupes carbamate lié à un atome de carbone d'un cycle aromatique à six chaînons à un atome de carbone d'un cycle aromatique à six chaînons non condensé
79.
CRYSTALLINE PROSTACYCLIN (IP) RECEPTOR AGONIST AND USES THEREOF
Described herein are crystalline forms of a prostacyclin (IP) receptor agonist compound, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist compound.
C07C 271/28 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec l'atome d'azote d'au moins un des groupes carbamate lié à un atome de carbone d'un cycle aromatique à six chaînons à un atome de carbone d'un cycle aromatique à six chaînons non condensé
A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
An apparatus (100) for printing a 3D model, comprising: a vat (106) configured to store a photocurable ink, wherein a bottom of the vat comprises an oxygen permeable membrane (105), and a printing platform (116) comprising: a base (118), and a mesh at a first side of the base, wherein an adhesion strength between a photocurable ink to the mesh is greater than an adhesion strength of the photocurable ink to the oxygen permeable membrane, wherein the platform is configured to be displaced from the oxygen permeable membrane to form a 3D model from the photocurable ink.
B29C 64/124 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant des couches de liquide à solidification sélective
A platform form an apparatus for printing a 3D model comprises a base and a print layer. The base has a first side where the first side of the base has a first surface roughness thereon. The print layer is coupled first side of the base and includes a surface. The surface of the print layer is distal from the base and has a second surface roughness which is greater than the first surface roughness so as to promote adhesion of the 3D model being printed on the platform.
The present invention provides transgenic animals (e.g., transgenic porcine animals), organs, tissues, and cells derived from the transgenic animals that are particularly useful for xenotransplantation therapies. In particular, the present invention provides transgenic porcine animals, as well as organs, tissues and cells derived from the transgenic porcine animals, which lack any expression of a functional alpha 1,3 galactosyltransferase (GTKO) gene and comprise at least six transgenes under the control of at least three promoters within a single multi-gene expression vector, and further comprise at least four additional genetic modifications. Also provided are methods of making the transgenic animals (e.g., transgenic porcine animals), and methods of using the transgenic animals, organs, tissues, and cells derived from the transgenic animals for xenotransplantation therapies and treating a disease or condition.
An apparatus (100) for printing a 3D model, comprising: a vat (106) configured to store a photocurable ink, wherein a bottom of the vat comprises an oxygen permeable membrane (105), and a printing platform (116) comprising: a base (118), and a mesh at a first side of the base, wherein an adhesion strength between a photocurable ink to the mesh is greater than an adhesion strength of the photocurable ink to the oxygen permeable membrane, wherein the platform is configured to be displaced from the oxygen permeable membrane to form a 3D model from the photocurable ink.
B29C 64/124 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant des couches de liquide à solidification sélective
A61K 31/27 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carbamiques ou thiocarbamiques, p. ex. méprobamate, carbachol, néostigmine
A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
A61K 31/335 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine
A61K 31/222 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine avec des composés ayant des groupes aromatiques, p. ex. dipivéfrine, ibopamine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/265 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carbonique, thiocarboniques, thiocarboxyliques, p. ex. acide thio-acétique, acide xanthogénique, acide trithiocarbonique
87.
METHODS AND COMPOSITIONS FOR IMPROVING ENDOTHELIAL CELL BARRIER
Described herein are methods and compositions for use in improving a vascular barrier of endothelial cells. The methods may include the use of barrier agonist compounds and improved techniques for culturing endothelial cells. The improved methods and compositions for culturing endothelial cells may include at least one or more of the following: an adenylyl cyclase activator; an activator of Sphingosine- 1 -phosphate (SIP) receptor internalization; a direct or indirect inducer of tight junction protein expression, and a direct or indirect inducer of adherens junction protein expression.
A printable composition for the manufacture of cell-receiving scaffolds comprising about 0.3 wt % to about 3.0 wt % of one or more collagens; about 5.0 wt % to about 40.0 wt % of one or more monomers; about 0.5 wt % to about 2.0 wt % of a photo initiator; and 0 wt % to about 75 wt % of a vehicle comprising a protic solvent, by weight of the printable composition; wherein the printable composition has a resolution of about 100 microns or less when printed, a photo speed (Dp/Ec) of about 0.1-5 mm (Dp) and about 10-100 mJ/cm2 (Ec) when printed, and a green strength of at least about 5 kPa after drying. The present technology further includes methods of manufacturing a three-dimensional cell-receiving scaffold using the printable composition.
B33Y 70/00 - Matériaux spécialement adaptés à la fabrication additive
B29C 64/124 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant des couches de liquide à solidification sélective
89.
METHODS AND COMPOSITIONS FOR IMPROVING ENDOTHELIAL CELL BARRIER
Described herein are methods and compositions for use in improving a vascular barrier of endothelial cells. The methods may include the use of barrier agonist compounds and improved techniques for culturing endothelial cells. The improved methods and compositions for culturing endothelial cells may include at least one or more of the following: an adenylyl cyclase activator; an activator of Sphingosine- 1 -phosphate (SIP) receptor internalization; a direct or indirect inducer of tight junction protein expression, and a direct or indirect inducer of adherens junction protein expression.
Described herein are methods and compositions for use in improving a vascular barrier of endothelial cells. The methods may include the use of barrier agonist compounds and improved techniques for culturing endothelial cells. The improved methods and compositions for culturing endothelial cells may include at least one or more of the following: an adenylyl cyclase activator; an activator of Sphingosine-1-phosphate (S1P) receptor internalization; a direct or indirect inducer of tight junction protein expression, and a direct or indirect inducer of adherens junction protein expression.
C07D 307/93 - Composés hétérocycliques contenant des cycles à cinq chaînons comportant un atome d'oxygène comme unique hétéro-atome du cycle condensés en ortho ou en péri avec des carbocycles ou avec des systèmes carbocycliques condensés avec un cycle autre qu'un cycle à six chaînons
92.
TRIPLY PERIODIC MINIMAL SURFACES FOR 3D PRINTED ORGANS AND TISSUES
An apparatus can include a triply periodic minimal surface. The apparatus can include a 3D scaffold formed from the triply periodic minimal surface. The apparatus can include one or more channels formed by the 3D scaffold. A method of forming a gas exchange unit can include printing a 3D scaffold formed from a triply periodic minimal surface. The 3D scaffold can include a vascular network configured to conduct a fluid. The 3D scaffold can include one or more channels configured to hold a gas. The vascular network can be embedded inside walls of the 3D scaffold. The one or more channels can be positioned between the walls of the 3D scaffold.
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
93.
TRIPLY PERIODIC MINIMAL SURFACES FOR 3D PRINTED ORGANS AND TISSUES
An apparatus can include a triply periodic minimal surface. The apparatus can include a 3D scaffold formed from the triply periodic minimal surface. The apparatus can include one or more channels formed by the 3D scaffold. A method of forming a gas exchange unit can include printing a 3D scaffold formed from a triply periodic minimal surface. The 3D scaffold can include a vascular network configured to conduct a fluid. The 3D scaffold can include one or more channels configured to hold a gas. The vascular network can be embedded inside walls of the 3D scaffold. The one or more channels can be positioned between the walls of the 3D scaffold.
A61F 2/00 - Filtres implantables dans les vaisseaux sanguinsProthèses, c.-à-d. éléments de substitution ou de remplacement pour des parties du corpsAppareils pour les assujettir au corpsDispositifs maintenant le passage ou évitant l'affaissement de structures corporelles tubulaires, p. ex. stents
B33Y 70/00 - Matériaux spécialement adaptés à la fabrication additive
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
94.
TRIPLY PERIODIC MINIMAL SURFACES FOR 3D PRINTED ORGANS AND TISSUES
An apparatus can include a triply periodic minimal surface. The apparatus can include a 3D scaffold formed from the triply periodic minimal surface. The apparatus can include one or more channels formed by the 3D scaffold. A method of forming a gas exchange unit can include printing a 3D scaffold formed from a triply periodic minimal surface. The 3D scaffold can include a vascular network configured to conduct a fluid. The 3D scaffold can include one or more channels configured to hold a gas. The vascular network can be embedded inside walls of the 3D scaffold. The one or more channels can be positioned between the walls of the 3D scaffold.
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
A method of printing a hydrogel scaffold is provided which includes providing a container containing an ink and a liquid that is immiscible with the ink; applying light from a light source to the ink to form a portion of the hydrogel scaffold, and applying light from a light source one or more additional times to produce one or more additional portions of the hydrogel scaffold.
B29C 64/106 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux
B29C 64/129 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant des couches de liquide à solidification sélective caractérisés par la source d'énergie à cet effet, p. ex. par irradiation globale combinée avec un masque
96.
ENHANCEMENT OF MSC IMMUNOMODULATORY PROPERTIES BY TREPROSTINIL
Provided are methods for treating or preventing vasculopathy comprising administering to a subject in need thereof, ac composition comprising a mesenchymal stem cell (MSC), or a part of a culture medium that has been in contact with the MSC and comprises one or more components of the MSC, or an exosome derived from the MSC. Pharmaceutical compositions suitable for such treatment is also provided.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A method of printing a hydrogel scaffold is provided which includes providing a container containing an ink and a liquid that is immiscible with the ink; applying light from a light source to the ink to form a portion of the hydrogel scaffold, and applying light from a light source one or more additional times to produce one or more additional portions of the hydrogel scaffold.
B29C 64/106 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux
B29C 64/129 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant des couches de liquide à solidification sélective caractérisés par la source d'énergie à cet effet, p. ex. par irradiation globale combinée avec un masque
98.
Two-phase 3D printing methods of forming biocompatible structures with immiscible liquids
A method of printing a hydrogel scaffold is provided which includes providing a container containing an ink and a liquid that is immiscible with the ink; applying light from a light source to the ink to form a portion of the hydrogel scaffold; and applying light from a light source one or more additional times to produce one or more additional portions of the hydrogel scaffold.
B29C 64/124 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant des couches de liquide à solidification sélective
B29K 105/00 - Présentation, forme ou état de la matière moulée
The present invention provides transgenic animals (e.g., transgenic porcine animals), organs, tissues, and cells derived from the transgenic animals that are particularly useful for xenotransplantation therapies. In particular, the present invention provides transgenic porcine animals, as well as organs, tissues and cells derived from the transgenic porcine animals, which lack any expression of a functional alpha 1,3 galactosyltransferase (GTKO) gene and comprise at least six transgenes under the control of at least three promoters within a single multi-gene expression vector, and further comprise at least four additional genetic modifications. Also provided are methods of making the transgenic animals (e.g., transgenic porcine animals), and methods of using the transgenic animals, organs, tissues, and cells derived from the transgenic animals for xenotransplantation therapies and treating a disease or condition.
Systems and methods are provided for evaluating a tissue that utilize a resistance to represent pressure of a fluid or gas passing through the tissue and a capacitance to represent compliance of the tissue.
G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/0205 - Évaluation simultanée de l'état cardio-vasculaire et de l'état d'autres parties du corps, p. ex. de l'état cardiaque et respiratoire
A61B 5/021 - Mesure de la pression dans le cœur ou dans les vaisseaux sanguins
A61M 5/172 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte électriques ou électroniques
